Last reviewed · How we verify

Zydus Lifesciences — Portfolio Competitive Intelligence Brief

Zydus Lifesciences (ZYDUSLIFE.NS) pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

ZYDUSLIFE.NS (NSE) 1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Januvia SITAGLIPTIN marketed Dipeptidyl Peptidase 4 Inhibitor [EPC] Dipeptidyl peptidase 4 Metabolic 2006-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Boehringer Ingelheim · 1 shared drug class
  3. Generic (originally Merck Serono/Lipha) · 1 shared drug class
  4. Institut für Pharmakologie und Präventive Medizin · 1 shared drug class
  5. University Medical Centre Ljubljana · 1 shared drug class
  6. Zhujiang Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zydus Lifesciences:

Cite this brief

Drug Landscape (2026). Zydus Lifesciences — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zydus-lifesciences. Accessed 2026-05-16.

Related